INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11101, 7728, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11102, 8496, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11103, 8898, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11104, 8902, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11105, 15842, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11106, 16810, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11107, 19975, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11108, 19976, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11109, 23628, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11110, 23629, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11111, 23630, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11112, 23631, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11113, 23635, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11114, 23637, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11115, 23639, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11116, 3424, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11117, 3425, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11118, 7728, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11119, 8496, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11120, 8898, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11121, 8902, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11122, 15842, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11123, 16810, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11124, 19975, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11125, 19976, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11126, 23628, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11127, 23629, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11128, 23630, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11129, 23631, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11130, 23635, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11131, 23637, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11132, 23639, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11133, 3424, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11134, 3425, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11135, 7728, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11136, 8496, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11137, 8898, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11138, 8902, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11139, 15842, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11140, 16810, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11141, 19975, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11142, 19976, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11143, 23628, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11144, 23629, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11145, 23630, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11146, 23631, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11147, 23635, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11148, 23637, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11149, 23639, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11150, 793, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11151, 4037, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11152, 8553, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11153, 8554, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11154, 8884, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11155, 8885, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11156, 9642, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11157, 14235, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11158, 16922, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11159, 16923, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11160, 16924, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11161, 16925, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11162, 16926, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11163, 18121, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11164, 23617, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11165, 23620, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11166, 23621, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11167, 23622, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11168, 25435, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11169, 28592, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11170, 28593, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11171, 28594, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11172, 28743, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11173, 28744, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11174, 29746, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11175, 30010, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11176, 30011, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11177, 33900, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11178, 793, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11179, 4037, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11180, 8553, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11181, 8554, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11182, 8884, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11183, 8885, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11184, 9642, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11185, 14235, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11186, 16922, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11187, 16923, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11188, 16924, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11189, 16925, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11190, 16926, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11191, 18121, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11192, 23617, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11193, 23620, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11194, 23621, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11195, 23622, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11196, 25435, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11197, 28592, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11198, 28593, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11199, 28594, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (11200, 28743, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', '', 'DDInter', 0);
